Biclonal gammopathy in a patient taking efalizumab for the treatment of psoriasis

Authors

Antonia Fthenakis, George Washington University
Kurt S. Wenk, George Washington University
Alison Ehrlich, George Washington UniversityFollow
Jeanny B. Aragon-Ching, George Washington UniversityFollow

Document Type

Journal Article

Publication Date

2013

Journal

Journal of Hematology and Thromboembolic Diseases

Volume

Volume 1

Inclusive Pages

Article number 106

Abstract

We report a patient who developed biclonal gammopathy of undetermined significance during treatment with
efalizumab for psoriasis. This plasma cell disorder was found during the evaluation of the patient’s complaint of mild lower extremity paresthesia. The gammopathy spontaneously remitted following cessation of therapy and has not recurred to date. Given the increasing use and development of biological agents for the treatment of psoriasis and other disorders, this finding and the mechanisms by which it may have occurred is of clinical significance.

Comments

Reproduced with permission of OMICS Publishing Group.

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.

APA Citation

Fthenakis, A., Wenk, K.S., Ehrlich, A., Aragon-Ching, J.B. (2013). Biclonal gammopathy in a patient taking efalizumab for the treatment of psoriasis. Journal of Hematology and Thromboembolic Diseases, 1:106.

Open Access

1